Heart failure (HF), a leading cause of mortality in patients with myocardial infarction (MI), is especially progressive in the 20-25% of post-MI patients with ischemic mitral regurgitation (IMR). IMR drives a vicious cycle of left ventricular (LV) dilatation and MR caused by leaflet tethering to the LV walls. Ongoing remodeling drive leads to frequent failure of standard annuloplasty ring therapy, indicating the need to treat the ventricle as well as the valve. Our prior work has shown that post-MI LV remodeling is exacerbated by the added MR-induced volume overload, with downregulation of SERCA2a, a key calcium cycling pump, and increased fibrosis. Upregulating SERCA2a with intracoronary adeno associated virus (AAV) reduces remodeling when given early and also with late MR repair. Fibrosis can be reduced by AAV.CCN5, which reverses functional deterioration in HF induced by pressure overload. This proposal considers two clinical scenarios: acute MI, with potential to limit early remodeling as stimulus for progressive remodeling and IMR; and later remodeling, to improve long- term results from surgical repair of IMR by addressing myocardial remodeling as well. The central hypothesis is that LV remodeling in an IMI-induced model of progressive heart failure with IMR can be reduced at both early and late stages through a synergistic approach improving both myocardial and interstitial components of heart failure. We will test the following hypotheses: 1) Early administration of SERCA2a, CCN5 or both at the time of ischemia-reperfusion injury can prevent the remodeling that occurs despite revascularization. This is supported by recent evidence for transgene uptake in this context, and by our preliminary evidence that early preventive therapy with the combined vectors safely reduces both local infarct deformation and the ensuing cycle of MR and global remodeling.
This aim simulates the scenario of patients with acute MI undergoing primary percutaneous intervention (PCI). 2) Upregulating SERCA2a, CCN5 or both can prevent or reverse remodeling in an established inferior MI model that produces important MR, simulating the clinical situation of treatment after remodeling has occurred, either early or late relative to compensatory pathway activation or exhaustion. 3) SERCA2a, CCN5 or both can prevent ongoing remodeling leading to recurrent MR when given during annuloplasty repair in an inferior MI model. LV remodeling and MR will be compared for ring alone, myocardial therapy alone (Aim 2), and the combination. In these aims we will address mechanistic hypotheses regarding CCN5 inhibition of fibrosis by decreasing post-MI endothelial-to-mesenchymal cell transformation and pro- fibrotic myofibroblast formation; SERCA2a reduction of remodeling by increasing contractility and decreasing apoptosis; and reduction of localized infarct deformation by early therapy in addition to reduced progression of global remodeling. The collaborative team combines strengths in surgical physiologic modeling, imaging and pathology of fibrosis, and myocardial biology with gene therapy. Results can support clinical studies of these strategies in patients undergoing mitral valve repair for ischemic MR and primary PCI for acute MI.
Heart failure (HF) is a leading cause of death in patients with heart attack and is especially progressive in the 20-25% of heart attack patients who develop regurgitation of the mitral valve that drives a vicious cycle of heart enlargement, weakening and fibrous scarring that limits the benefit of the standard surgical therapy for the valve in this condition. Based on studies of underlying mechanisms, we propose to improve the heart function of patients with this mitral condition caused by heart attack by treating the heart muscle as well as the valve, and by treating both the contracting heart cells and their surrounding scar-forming cells together in way that may produce the greatest benefit, especially providing early treatment following heart attack to prevent the vicious downhill cycle to heart failure in a large number of patients. This proposal has assembled a research team with the key expertise and resources to address this public health problem by using gene transfer techniques to strengthen the heart and prevent heart failure in patients with coronary artery disease.
|Yoshitani, Hidetoshi; Isotani, Akihiro; Song, Jae-Kwan et al. (2018) Surgical as Opposed to Transcatheter Aortic Valve Replacement Improves Basal Interventricular Septal Hypertrophy. Circ J 82:2887-2895|
|Watanabe, Shin; Fish, Kenneth; Kovacic, Jason C et al. (2018) Left Ventricular Unloading Using an Impella CP Improves Coronary Flow and Infarct Zone Perfusion in Ischemic Heart Failure. J Am Heart Assoc 7:|
|Bartko, Philipp E; Pavo, Noemi; Pérez-Serradilla, Ana et al. (2018) Evolution of secondary mitral regurgitation. Eur Heart J Cardiovasc Imaging 19:622-629|
|Jarrah, Andrew A; Schwarskopf, Martina; Wang, Edward R et al. (2018) SDF-1 induces TNF-mediated apoptosis in cardiac myocytes. Apoptosis 23:79-91|
|Ceholski, Delaine K; Turnbull, Irene C; Kong, Chi-Wing et al. (2018) Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol 119:147-154|
|Kagan, Heather J; Belekdanian, Varujan D; Chen, Jiqiu et al. (2018) Coronary capillary blood flow in a rat model of congestive heart failure. J Appl Physiol (1985) 124:632-640|
|Kim, Dae-Hee; Dal-Bianco, Jacob P; Aikawa, Elena et al. (2018) Mitral Valve Adaptation: Can We Win the Race? Circ Cardiovasc Imaging 11:e007642|
|Oh, Jae Gyun; Watanabe, Shin; Lee, Ahyoung et al. (2018) miR-146a Suppresses SUMO1 Expression and Induces Cardiac Dysfunction in Maladaptive Hypertrophy. Circ Res 123:673-685|
|Chamberlain, Kyle; Riyad, Jalish M; Garnett, Tyrone et al. (2018) A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. Hum Gene Ther 29:927-937|
|Jeong, Dongtak; Yoo, Jimeen; Lee, Philyoung et al. (2018) miR-25 Tough Decoy Enhances Cardiac Function in Heart Failure. Mol Ther 26:718-729|
Showing the most recent 10 out of 70 publications